Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
This study will analyze the clinical indicators, imaging data, and serum biomarkers of Alzheimer's disease (AD) patients receiving different doses of the medication before and after treatment. It aims to clarify whether the therapeutic efficacy in the low-dose group is equivalent to that in the recommended-dose group, and meanwhile to determine the optimal dose range for effective pharmacotherapy.
Key Details
Gender
All
Age Range
50 Years - 85 Years
Study Type
OBSERVATIONAL
Enrollment
140
Start Date
2026-04-30
Completion Date
2028-01-31
Last Updated
2026-04-01
Healthy Volunteers
No
Interventions
Lecanemab 10 mg/kg
Lecanemab Injection Concentrate Solution (active ingredient at 100 mg/mL) is provided as a sterile aqueous solution containing 100 mg/mL of Lecanemab, 50 mmol/L citric acid, 350 mmol/L arginine/arginine hydrochloride, and 0.05% (w/v) polysorbate 80, with a pH of 5.0, and each vial is capable of being drawn into a volume of 5 mL.
Lecanemab 5-10mg/kg
Lecanemab Injection Concentrate Solution 5-10mg/kg, the dose based on the actual dosage administered to patients in the real-world setting
Locations (1)
Human Subject Research Ethics Committee, 2ndAffiliated Hospital, School of Medicine, Zhejiang University,
Hangzhou, Zhejiang, China